Sun Pharmaceuticals rose by around 2 per cent to touch Rs 1,500 on Wednesday after the firm received nod from the US Food and Drug Administration for its abbreviated new drug application to market the generic version of the carboplatin injection.
The 10mg/ml injections are equivalent to Bristol-Myers Squibb's Paraplatin injections, which are mainly prescribed for initial and secondary therapy in patients with advanced ovarian carcinoma. These injections have annual sales of about $45 million in the US. The stock hit an intra-day high of Rs 1,509.9 and a low of Rs 1,466 with trading volumes of 17,259.
